145 related articles for article (PubMed ID: 8876871)
21. Safety and efficacy of Intralipid emulsions of amphotericin B.
Herbrecht R; Letscher V
J Antimicrob Chemother; 1997 Jul; 40(1):137-9. PubMed ID: 9249219
[No Abstract] [Full Text] [Related]
22. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis.
Mistro S; Maciel Ide M; de Menezes RG; Maia ZP; Schooley RT; Badaró R
Clin Infect Dis; 2012 Jun; 54(12):1774-7. PubMed ID: 22491505
[TBL] [Abstract][Full Text] [Related]
23. [Pulmonary mucormycosis: benefit of aerosol amphotericin B?].
Furco A; Mouchet B; Carbonnelle M; Vallerand H
Rev Mal Respir; 2001 Jun; 18(3):309-13. PubMed ID: 11468594
[TBL] [Abstract][Full Text] [Related]
24. [Amphotericin B into parenteral lipid emulsions. Galenic stability of mixtures. Preliminary results].
Blancard A; Monges P; Lacarelle B; Denis JP; Bongrand MC; Ragon CH; Gouin F
Pathol Biol (Paris); 1996 May; 44(5):384-8. PubMed ID: 8758481
[TBL] [Abstract][Full Text] [Related]
25. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
[TBL] [Abstract][Full Text] [Related]
26. Reader clarifies the use of amphotericin B.
Madej T
Oncol Nurs Forum; 1998 May; 25(4):653. PubMed ID: 9599340
[No Abstract] [Full Text] [Related]
27. Anaphylactic reaction to liposomal amphotericin B.
Vaidya SJ; Seydel C; Patel SR; Ortin M
Ann Pharmacother; 2002 Sep; 36(9):1480-1. PubMed ID: 12196074
[No Abstract] [Full Text] [Related]
28. An elevated pro-inflammatory cytokine response is linked to development of amphotericin B-induced nephrotoxicity.
Chai LY; Netea MG; Tai BC; Khin LW; Vonk AG; Teo BW; Schlamm HT; Herbrecht R; Donnelly JP; Troke PF; Kullberg BJ
J Antimicrob Chemother; 2013 Jul; 68(7):1655-9. PubMed ID: 23557927
[TBL] [Abstract][Full Text] [Related]
29. Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule.
Altmannsberger P; Holler E; Andreesen R; Krause SW
J Antimicrob Chemother; 2007 Jul; 60(1):180-2. PubMed ID: 17537868
[No Abstract] [Full Text] [Related]
30. Nephrotoxicity of amphotericin B desoxycholate.
Girmenia C; Gentile G; Micozzi A; Martino P
Clin Infect Dis; 2001 Sep; 33(6):915-6. PubMed ID: 11512101
[No Abstract] [Full Text] [Related]
31. Poor immediate tolerability of amphotericin B lipid emulsion in patients with haematological malignancies. Haematology-Microbiology Group.
Laverdière M; Habel F; Weiss K; Delorme J; Dubois G; Gagnon N; Bélanger R
J Antimicrob Chemother; 1997 Dec; 40(6):910-2. PubMed ID: 9462450
[No Abstract] [Full Text] [Related]
32. Coadministration of Liposomal Amphotericin B and Contrast Medium Does Not Increase Risk of Kidney Injury.
O'Horo JC; Osmon DR; Abu Saleh OM; Marcelin JR; Gharaibeh KA; Hamadah AM; Barwise AK; Kayhart BM; McDonald JS; McDonald RJ; Leung N
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533242
[TBL] [Abstract][Full Text] [Related]
33. Acrocyanosis developed with amphotericin B deoxycholate but not with amphotericin B lipid complex.
Ozaras R; Yemisen M; Mete B; Mert A; Ozturk R; Tabak F
Mycoses; 2007 May; 50(3):242. PubMed ID: 17472626
[No Abstract] [Full Text] [Related]
34. Experience with community-based amphotericin B infusion therapy.
Malani PN; Depestel DD; Riddell J; Bickley S; Klein LR; Kauffman CA
Pharmacotherapy; 2005 May; 25(5):690-7. PubMed ID: 15899731
[TBL] [Abstract][Full Text] [Related]
35. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients.
Moreau P; Milpied N; Fayette N; Ramée JF; Harousseau JL
J Antimicrob Chemother; 1992 Oct; 30(4):535-41. PubMed ID: 1490923
[TBL] [Abstract][Full Text] [Related]
36. Macrophage activation syndrome induced by prolonged treatment with liposomal amphotericin B.
Jung G; Reverter E; Fernández J
Med Clin (Barc); 2018 Jul; 151(2):84-85. PubMed ID: 29241868
[No Abstract] [Full Text] [Related]
37. Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment.
Falci DR; dos Santos RP; Wirth F; Goldani LZ
Mycoses; 2011 Mar; 54(2):91-8. PubMed ID: 19878457
[TBL] [Abstract][Full Text] [Related]
38. Amphotericin B-related nephrotoxicity in low-risk patients.
Berdichevski RH; Luis LB; Crestana L; Manfro RC
Braz J Infect Dis; 2006 Apr; 10(2):94-9. PubMed ID: 16878259
[TBL] [Abstract][Full Text] [Related]
39. Is amphotericin B test dosing needed?
Griswold MW; Briceland LL; Stein DS
Ann Pharmacother; 1998 Apr; 32(4):475-7. PubMed ID: 9562144
[No Abstract] [Full Text] [Related]
40. Precipitation of amphotericin B from i.v. fat emulsion.
Heide PE
Am J Health Syst Pharm; 1997 Jun; 54(12):1449. PubMed ID: 9194992
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
